Search Orphan Drug Designations and Approvals
-
| Generic Name: | highly selective inhibitor of the tyrosine kinase BTK |
|---|---|
| Date Designated: | 02/25/2025 |
| Orphan Designation: | treatment of mastocytosis |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Telios Pharma, Inc. 275 Shoreline Drive Suite 325 Redwood City, California 94065 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







